文献速递神经肿瘤脑血管病外科

靶向治疗或化疗联用立体定向放射外科对非小细胞肺癌脑转移预后的影响

Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC).
PubMed 文献 · J Neurooncol · 2025-12-23

该10年回顾性队列研究纳入61例非小细胞肺癌脑转移患者,比较靶向治疗与标准化疗在联用立体定向放射外科(SRS)时对预后的影响。靶向治疗组脑无进展生存(brain-PFS)显著优于化疗组(P=0.001),5年总生存(OS)40% vs 19%(P=0.06),12个月后局部脑肿瘤控制率76% vs 29%(P=0.012)。

要点

  • 靶向治疗联用SRS显著改善脑转移患者的脑无进展生存。
  • 12个月后靶向组局部脑肿瘤控制率76%,化疗组29%(P=0.012)。
  • 5年OS靶向组40% vs 化疗组19%,但差异未达统计学显著(P=0.06)。

核心结论

  • 靶向治疗联用SRS可显著改善非小细胞肺癌脑转移患者的治疗反应和生存率。
  • 联合两种方式对局部和远端转移均产生更好反应、更长生存及更优整体状态。

研究设计与样本

  • 10年回顾性队列研究,纳入61例18岁及以上非小细胞肺癌脑转移患者。
  • 按接受靶向治疗(依据肿瘤细胞突变或免疫表达)或标准化疗分为两组,所有治疗与SRS同期或SRS后2个月内进行。

主要发现

  • 靶向治疗组脑无进展生存(brain-PFS)显著优于化疗组(P=0.001)。
  • 5年OS靶向组40% vs 化疗组19%,差异未达统计学显著(P=0.06)。
  • 前6个月内50%化疗组患者出现脑转移疾病进展。
  • 12个月后靶向组76%(22/30)维持局部脑肿瘤控制,化疗组29%(9/31)(P=0.012)。
  • 远端脑转移控制率靶向组13%(3/23),化疗组无响应或控制;两组系统反应或系统PFS无显著差异。

临床怎么用

  • 对非小细胞肺癌脑转移患者,可考虑靶向治疗联用SRS以改善局部脑控制。
  • 靶向治疗选择需依据肿瘤细胞突变或免疫表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies suggest that stereotactic radiosurgery (SRS) increases penetration of systemic drugs into the CNS, and induces immune response to tumor-specific antigens on the surface of tumor cells. Radiation treatment concomitant with immunotherapies and biological treatments for brain metastases (BM) can enhance the body’s immune system to fight the tumor. METHODS: A 10-year retrospective cohort study of 61 patients, 18 years and older, with BM from primary non-small cell lung cancer (NSCLC) tumors was divided into those who received targeted therapy according to tumor cell mutations or immunoexpression, and those who received standard chemotherapy for metastatic NSCLC with BM. All patients received the treatment concomitant with or within 2 months following the SRS procedure. Brain progression-free survival (brain-PFS), overall survival (OS), and Karnofsky performance score (KPS) were compared between the two groups. RESULTS : Significant differences favoring targeted therapy were observed in brain-PFS (P = 0.001); Five-year OS was 40% vs. 19%, indicating a non-significant trend toward improved survival (P = 0.06). Within the first 6 months, 50% of the chemotherapy group experienced BM disease progression. In contrast, patients receiving targeted therapies showed brain-PFS below 50% over 12 months with a 5-year survival rate of 40%, compared to 19% in the chemotherapy group. After 12 months, 76% of the target group maintained localized brain tumor control (22/30) versus 29% in chemotherapy (9/31) (P = 0.012). Distal BM control was seen in 13% of the targeted therapy group (3/23), while none in chemotherapy exhibited response or control. No significant differences were found in systemic response or systemic PFS between the groups. CONCLUSION : Targeted therapies together with SRS for BM in patients with primary NSCLC tumors significantly improved response and survival rates. Combining these two modalities produced greater response to treatment for both local and distal metastases, longer survival, and improved overall performance compared to the traditional radiation and chemotherapy. CLINICAL TRIAL NUMBER: Not applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ron GN, Ron IG, Kantor H, et al. Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC). J Neurooncol. 2025. PMID: 41436648. doi:10.1007/s11060-025-05346-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。